| abstract |
The present invention provides catechol bioequivalent compounds that are potential inhibitors of protein tyrosine kinases (PTKs). The present invention further provides a method of inhibiting PTK, eg, receptor protein tyrosine kinase (RTK), comprising administering a catechol biological equivalent. This catechol bioequivalent compound is useful for the treatment or prevention of PTK-related disease states, particularly protein tyrosine kinase-related disorders associated with PTK-mediated signaling pathway defects. |